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ABSTRACT
The dopamine D1 receptor–D3 receptor (D1R-D3R) heteromer
is being considered as a potential therapeutic target for
neuropsychiatric disorders. Previous studies suggested that
this heteromer could be involved in the ability of D3R agonists
to potentiate locomotor activation induced by D1R agonists.
It has also been postulated that its overexpression plays
a role in L-dopa–induced dyskinesia and in drug addiction.
However, little is known about its biochemical properties. By
combining bioluminescence resonance energy transfer, bi-
molecular complementation techniques, and cell-signaling
experiments in transfected cells, evidence was obtained for
a tetrameric stoichiometry of the D1R–D3R heteromer,
constituted by two interacting D1R and D3R homodimers
coupled to Gs and Gi proteins, respectively. Coactivation of
both receptors led to the canonical negative interaction at the
level of adenylyl cyclase signaling, to a strong recruitment of
b-arrestin-1, and to a positive cross talk of D1R and D3R
agonists at the level of mitogen-activated protein kinase
(MAPK) signaling. Furthermore, D1R or D3R antagonists
counteracted b-arrestin-1 recruitment and MAPK activation
induced by D3R and D1R agonists, respectively (cross-
antagonism). Positive cross talk and cross-antagonism at
the MAPK level were counteracted by specific synthetic
peptides with amino acid sequences corresponding to D1R
transmembrane (TM) domains TM5 and TM6, which also
selectively modified the quaternary structure of the D1R-D3R
heteromer, as demonstrated by complementation of hemi-
proteins of yellow fluorescence protein fused to D1R and
D3R. These results demonstrate functional selectivity of
allosteric modulations within the D1R-D3R heteromer, which
can be involved with the reported behavioral synergism of
D1R and D3R agonists.
Introduction
Most evidence indicates that, as for family C G protein–
coupled receptors (GPCRs), family A GPCRs can form
homodimers and heteromers. Homodimers seem to be
a predominant species with potential dynamic formation of
higher-order oligomers, particularly tetramers (Milligan,
2013; Ferré et al., 2014). Although monomeric GPCRs can
activate G proteins, the pentameric structure constituted by
one GPCR homodimer and one heterotrimeric G protein may
provide a main functional unit at the plasma membrane, and
oligomeric entities can be viewed as multiples of dimers
(Ferré et al., 2014). It still needs to be resolved whether GPCR
heteromers are preferentially heterodimers or whether they
are mostly constituted by heteromers or Q:2homodimers. Allo-
steric mechanisms determine amultiplicity of possible unique
pharmacological properties of GPCR homomers and
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heteromers. Some general mechanisms seem to apply,
particularly at the level of ligand-binding properties (Ferré
et al., 2014). Furthermore, in addition to ligand-binding
properties, unique properties for each GPCR oligomer emerge
in relation to different intrinsic efficacy of ligands for different
signaling pathways (functional selectivity) (Ferré et al., 2014).
Previous studies have provided evidence for the expression of
dopamine D1 receptor (D1R) and D3 receptor (D3R) hetero-
mers in mammalian transfected cells and suggested some
biochemical findings are related to D1R-D3R receptor
oligomerization. Those findings include a D3R agonist-
mediated increase in the affinity of D1R agonists and
a potentiation of D1R agonist-mediated signaling trough
adenylyl cyclase (Fiorentini et al., 2008; Marcellino et al.,
2008). It was hypothesized that these receptor-receptor
interactions could underlie some behavioral findings, such
as the selective synergistic locomotor activation of D1R and
D3R agonists observed in reserpinized mice (Marcellino et al.,
2008).
Demonstration of the functional significance of receptors
heteromers is becoming an important goal in GPCR research.
One main reason is their possible use as targets for drug
development, because of their unique biochemical properties.
Molecular or chemical tools that destabilize the quaternary
structure of the heteromer can be used to ascertain a bio-
chemical property of the GPCR heteromer (Ferré et al., 2009,
2014). This can be achieved by introducing mutations of key
determinant residues at the oligomerization interfaces or
using competing peptides with the sequence of specific
receptor domains putatively involved in receptor oligomeri-
zation (Hebert et al., 1996; Baneres and Parello, 2003; Azdad
et al., 2009; Pei et al., 2010; He et al., 2011).
In the present study, evidence was obtained for a minimal
tetrameric stoichiometry of the heteromer, comprised of D1R
and D3R homodimers able to couple to Gs and Gi proteins,
respectively. By using selective peptides with the sequence of
specific transmembrane domains (TM) of the D1R, we were
able to demonstrate ligand-induced allosteric interactions in
the D1R-D3R heteromer (positive cross talk and cross-
antagonism) that constitute specific biochemical character-
istics of the D1R-D3R heteromer. These allosteric interactions
selectively modulated mitogen-activated protein kinase
(MAPK) signaling and were also observed at the level of
b-arrestin-1 recruitment, but not at the level of G protein
coupling or adenylyl cyclase signaling. The results demon-
strate the existence of functional selectivity of allosteric
modulations within the D1R-D3R heteromer. These allosteric
modulations can have implications for the treatment of
several neuropsychiatric disorders, because the D1R-D3R
heteromer is being considered as a target for drug de-
velopment in Parkinson’s disease and drug addiction
(Fiorentini et al., 2010; Ferré et al., 2010, 2014).
Materials and Methods
CODA-RET AssayQ:3 . The cDNAs for human D1R, D3R, and Gas
short were obtained from www.cdna.org. D1R and D3R were tagged
with signal peptide (Guo et al., 2003), followed by aMyc epitope tag for
D1R (SM hereafter) or Flag epitope tag for D3R (SF hereafter) using
standard molecular biology procedures. The cDNAs encoding full-
length Renilla luciferase 8 (Rluc; provided by S. Gambhir, Standford
University, Standford, CA) or hemitruncated proteins corresponding
to fragments L1 (amino acids 1–229) or L2 (amino acids 230–311)
were fused in frame C terminus of SM-D1R or SF-D3R (in the case of
SF-D3R following a linker sequence between the receptor and the
luciferase) in the pcDNA3.1 vector. The following human G protein
constructs were used: Gai1-mVenus with mVenus inserted at position
91, Gas short-mVenus (Gass-mVenus) with mVenus inserted at
position 154, untagged Gb1, and untagged Gg2. All the constructs
were confirmed by sequencing analysis. Several constructs were
shared by J. Javitch (Columbia University, New York, NY; D1R Rluc
split constructs), C. Gales at INSERM (Toulouse, France; Gai1
construct), and N. Lambert (Georgia Regents University, Augusta,
GA; Gass construct). A constant amount of plasmid cDNA (15 mg) was
transfected into human embryonic kidney (HEK) cells (HEK-293)
using polyethylenimine (PEI; Sigma-Aldrich, St. Louis, MO) in a 1 to 3
ratio in 10-cm dishes. Cells were maintained in culture with
Dulbecco’s modified Eagle’s medium supplemented with 10% fetal
bovine serum. The transfected amount and ratio among the receptor-
L1, receptor-L2, Ga, Gb1, and Gg2 were optimized by testing various
ratios of plasmids encoding the different sensors. Experiments were
performed ∼48 hours post-transfection.
CODA-RET Q:4uses a Ga protein fused to yellow fluorescent protein
variant (mVenus) as an acceptor for energy transfer from protein
fused to Rluc and was measured by a bioluminescence resonance
energy transfer (BRET) process, as previously described (Guo et al.,
2008). As shown in the cartoons from Fig. 1, bimolecular complemen-
tation of two different receptor-fused hemiproteins corresponding to
the N-teminal and the C-terminal domains of Rluc was used as BRET
donor. RET took place between complemented luciferase complex and
Ga-mVenus. Receptor ligand-induced changes in BRET were mea-
sured. Briefly, cells were harvested, washed, and resuspended in
phosphate-buffered saline. Approximately 200,000 cells/well were
distributed in 96-well plates, and 5 mM coelenterazine H (substrate
for luciferase) was added to each well. One minute after addition of
coelenterazine H, ligands were added to each well. Antagonists were
added 15 minutes before the addition of agonist. The fluorescence of
the acceptor was quantified (excitation at 500 nm and emission at 540
nm for 1-second recording) 2 minutes after a ligand was added in
a Mithras LB940 (Berthold Technologies, Bad Wilbad, Germany). In
parallel, the BRET signal from the same batch of cells was determined
as the ratio of the light emitted by mVenus (510–540 nm) over that
emitted by Rluc8 (485 nm). Results are expressed as the BRET change
produced by the corresponding drug minus BRET in the absence of
the drug. Data and statistical analysis was performed with Prism 5
(GraphPad Software Q:5).
Fusion Proteins. Sequences encoding amino acid residues 1–155
and 155–238 of the Venus variant of yellow fluorescence protein (YFP)
and amino acids residues 1–229 and 230–311 of Rluc protein were
subcloned in the pcDNA3.1 vector to obtain YFP and Rluc hemi-
truncated proteins. The human cDNAs for D1R and D3R, cloned into
pcDNA3.1, were amplified without their stop codons using sense and
antisense primers harboring unique EcoRI and BamHI. The amplified
fragment corresponding to D1R was subcloned to be in-frame with
restriction sites of pcDNA3.1-Rluc, pcDNA3.1-cRluc, pcDNA3.1-
nRluc, pcDNA3.1-cYFP, or pcDNA3.1-nYFP to give plasmids that
express D1R fused to Rluc or to hemitruncated proteins on the C-
terminal end of the receptor (D1R-cRluc, D1R-nRluc, D1R-cYFP, or
D1R-nYFP). To obtain a plasmid that expresses D1R fused to Rluc on
the C-terminal end of the receptor (D1R-Rluc), the cDNAs for D1R
were amplified without their stop codons using sense and antisense
primers harboring unique HindIII and BamHI, and the amplified
fragment was subcloned to be in-frame with restriction sites of a Rluc-
expressing vector (pRluc-N1; PerkinElmer, Wellesley, MA). The
amplified fragment corresponding to D3R was subcloned to be in-
frame with BamHI and EcoRI restriction sites of pcDNA3.1-cYFP or
pcDNA3.1-nYFP to give plasmids that express D3R fused to YFP or to
hemitruncated proteins on the C-terminal end of the receptor (D3R-
YFP, D3R-cYFP, and D3R-nYFP). The receptor-fusion protein
expression and function were tested by confocal microscopy and by
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second messengers, extracellular signal-regulated kinases (ERK)1/2
phosphorylation, or cAMP production, as described previously
(Marcellino et al., 2008; Ferrada et al., 2009). Human b-arrestin-1-
Rluc6, cloned in the pcDNA3.1 RLuc vector (pRLuc-N1 PerkinElmer),
was generously provided by M. Castro (Santiago de Compostela
University, Galicia, Spain).
Cells and Cell Clones. To obtain cells expressing D1R, D3R, or
D1R-D3R, we first cloned D1R-Rluc, D3R-YFP, or D3R-YFP-D1R-
Rluc plasmids in a vector containing a FLP-FRT site, a hygromicin
resistance gene, and, only in the vector containing both receptors, an
internal ribosomal entry site placed between receptors. These vectors
were cotransfected in HEK-293 cells with the Flp recombinase
expression vector pOG44 (1 mg/9 mg) to obtain FLP-FRT-HEK stable
cell lines expressing D1R-Rluc (D1R cells), D3R-YFP (D3R cells), or
both receptors (D1R-D3R cells). Transfection was performed using
lipofectamine (Invitrogen, Paisley, Scotland) method following the
instructions of the supplier. Twenty-four hours after transfection, the
selection antibiotic was added (1000 mg/ml hygromicin B; Invitrogen).
Antibiotic-resistant clones were isolated, and, after an appropriate
number of passages, stable cell lines were selected and characterized
by radioligand binding, as indicated in Results.
Cell Culture and Transient Transfection. Wild-type HEK-293
cells and D1R, D3R, and D1R-D3R clones were grown in Dulbecco’s
modified Eagle’s medium (Gibco, Paisley, Scotland) supplemented
with 2 mM L-glutamine, 100 mg/ml sodium pyruvate, 100 U/ml
penicillin/streptomycin, minimum essential medium Q:6nonessential
amino acids solution (1/100), and 5% (v/v) heat-inactivated fetal
bovine serum (Invitrogen, Carlsbad, CA). For cell clones, the
corresponding selection antibiotic was added in the culture medium
(300 mg/ml hygromicin B). All cells were maintained at 37°C in an
atmosphere of 5% CO2. HEK-293 cells growing in 6-well dishes were
transiently transfected with the corresponding fusion protein cDNA
by the PEI method (Carriba et al., 2008). To control the cell number,
sample protein concentration was determined using a Bradford assay
kit (Bio-Rad, Munich, Germany) and bovine serum albumin dilutions
as standards. For adenylyl cyclase 5 (AC5) transfection, HEK-293
cells growing in 6-well dishes were transiently transfected with
a plasmid encoding for AC5 by the lipofectamine (Invitrogen) method
following the instructions of the supplier. AC5 cDNA (Robinson and
Caron, 1997) was generously provided by Y. Ishikawa and K. Suita
(Yokohama City University, Yokohama, Japan).
Fluorescence Complementation Assays. After 48 hours of
transient transfection with 1 mM cDNA encoding for D3R-nYFP and
D1R-cYFP, D1R-nYPF and D3R-cYFP, D3R-cYFP and D3R-nYFP, or
D1R-cYFP and D1R-nYFP, HEK-293 cells were treated or not with
the indicated TAT peptides (4 mM) for 60minutes at 37°C. To quantify
protein-reconstituted YFP expression, cells (20 mg protein) were
distributed in 96-well microplates (black plates with a transparent
bottom; Porvair, King’s Lynn, UK), and fluorescence was read in
a Fluoro Star Optima Fluorimeter (BMG Labtechnologies, Offenburg,
Germany) equipped with a high-energy xenon flash lamp, using a 10-
nm bandwidth excitation filter at 400-nm reading. Protein fluores-
cence expression was determined as fluorescence of the sample minus
the fluorescence of cells not expressing the fusion proteins (basal).
Cells expressing D1R-cVenus and nVenus or D3R-nVenus and cVenus
showed a fluorescence level not different from nontransfected cells.
BRET and BRET with Bimolecular Luminescence and
Fluorescence Complementation Assays. For BRET and BRET
with bimolecular luminescence and fluorescence complementation
assays, HEK-293T cells were transiently cotransfected with a con-
stant amount of cDNA encoding for proteins fused to RLuc, nRLuc, or
cRLuc, and with increasing amounts of the cDNA corresponding to
proteins fused to YFP, nYFP, or cYFP (see figure legends). To quantify
protein-YFP expression or complemented YFP expression, cells (20mg
protein) were distributed in 96-well microplates (black plates with
a transparent bottom) and fluorescence was read in a Fluo Star
Optima Fluorimeter (BMG) equipped with a high-energy xenon flash
lamp, using a 10-nm bandwidth excitation filter at 400-nm reading.
Fig. 1. Gs and Gi protein coupling to D1R-D3R heteromer determined by
CODA-RET experiments. BRET between complemented hemitruncated
Rluc (L1 and L2 are the N-terminal and the C-terminal domains of Rluc,
respectively) and G protein-YFP, as indicated in the cartoons at the top,
was determined in HEK-293 cells expressing the following: (A) Gai-YFP
(Gi1Y), D3R-L1 and D3R-L2 (black symbols), or D1R-L2 (orange symbols)
or (B) Gass-YFP (GssY), D1R-L2 and D1R-L1 (black symbols), or D3R-L1
(orange symbols). Cells were preincubated for 15 minutes at room
temperature with medium (filled symbols) or with 1 mM D3R antagonist
raclopride (A, orange open symbol) or the D1R antagonist SCH 23390 (B,
orange open symbol) before the addition of increasing concentrations of
D3R agonist quinpirole (A) or D1R agonist SKF 38393 (B). To the BRET
values for each agonist concentration was subtracted the BRET value in
the absence of ligands. Values are means 6 S.E.M. (n = 3–5).
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Relative fluorescence values were given as fluorescence of the sample
minus the fluorescence of cells expressing the BRET donor alone. For
BRET measurements, the equivalent of 20 mg cell suspension was
distributed in 96-well microplates (Corning 3600, white plates;
Sigma-Aldrich), and 5 mM coelenterazine H (Molecular Probes,
Eugene, OR) was added. After 1 minute for BRET or after 5 minutes
for BRET with bimolecular luminescence and fluorescence comple-
mentation, the readings were collected using a Mithras LB 940 that
allows the integration of the signals detected in the short-wavelength
filter at 485 nm (440–500 nm) and the long-wavelength filter at 530
nm (510–590 nm). To quantify protein-RLuc or protein-reconstituted
RLuc expression, luminescence readings were also performed after 10
minutes of adding 5 mM coelenterazine H. The net BRET is defined as
[(long-wavelength emission)/(short-wavelength emission)] 2 Cf,
where Cf corresponds to [(long-wavelength emission)/(short-
wavelength emission)] for the donor construct expressed alone in
the same experiment. BRET is expressed as milli-BRET units (net
BRET  1000).
b-Arrestin-1 Recruitment. Arrestin recruitment was deter-
mined by BRET experiments in HEK-293T cells 48 h after trans-
fection with the indicated amounts of cDNA corresponding to D1R,
D3R-YFP, and b-arrestin-1-Rluc. Cells (20 mg total protein from a cell
suspension per well in 96-well microplates) were not treated or
treated for 15 minutes with the indicated antagonists, and 5 mM
coelenterazine H was added before stimulation with the agonist for 10
minutes. BRET between b-arrestin 1-Rluc and D3R-YFP was de-
termined, as above.
ERK1/2 Phosphorylation. Cell clones were cultured overnight in
serum-free medium before the addition of any agent and were not
treated or treated with the indicated TAT peptides TM5, TM6, and
TM7 (4 mM) for 60 minutes at 37°C. When indicated, cells were
treated overnight with 10 ng/ml pertussis toxin (PTX) or 100 ng/ml
cholera toxin (CTX). After that, cells were incubated with the
indicated antagonist for 15 minutes at 37°C and then activated for 7
minutes with the indicated agonist. Cells were rinsed with ice-cold
phosphate-buffered saline and lysed by the addition of 500 ml ice-cold
lysis buffer (50 mM Tris-HCl [pH 7.4], 50 mM NaF, 150 mM NaCl, 45
mM b-glycerophosphate, 1% Triton X-100, 20 mMphenyl-arsine oxide,
0.4 mM NaVO4, and protease inhibitor cocktail). The cellular debris
was removed by centrifugation at 13,000 g for 5 minutes at 4°C, and
the protein was quantified by the bicinchoninic acid method using
bovine serum albumin dilutions as standard. To determine the level of
ERK1/2 phosphorylation, equivalent amounts of protein (10 mg) were
separated by electrophoresis on a denaturing 10% SDS-
polyacrylamide gel and transferred onto PVDF-FLQ:7 membranes.
Odyssey blocking buffer (LI-COR Biosciences, Lincoln, NE) was then
added, and themembranewas rocked for 90minutes. Themembranes
were then probed with a mixture of a mouse anti–phospho-ERK1/2
antibody (1:2500; Sigma-Aldrich) and rabbit anti-ERK1/2 antibody
that recognizes both phosphorylated and nonphosphorylated ERK1/2
(1:40,000; Sigma-Aldrich) for 3 hours minimum or overnight. The 42-
and 44-kDa bands corresponding to ERK1 and ERK2 were visualized
by the addition of a mixture of IRDye 800 (anti-mouse) antibody (1:
10,000; Sigma-Aldrich) and IRDye 680 (anti-rabbit) antibody (1:
10,000; Sigma-Aldrich) for 1–2 hours and scanned by the Odyssey
infrared scanner (LICOR Biosciences). Band densities were quanti-
fied using the scanner software and exported to Excel (Microsoft,
Redmond, WA). The level of phosphorylated ERK1/2 isoforms was
normalized for differences in loading using the total ERK1/2 protein
band intensities.
Radioligand-Binding Experiments. Binding experiments were
performed with cell membrane suspensions (0.2 mg protein/ml) at 25°C
in 50mMTris-HCl buffer, pH 7.4, containing 10mMMgCl2 or with this
buffer also supplemented with 120 mM NaCl and 5 mM KCl for
raclopride binding. For saturation experiments, membranes were
incubated with increasing free concentrations of the D1R antagonist
[3H](R)-(1)-7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahy-
dro-1H-3-benzazepine hydrochloride (SCH 23390; 70.5 Ci/mmol;
PerkinElmer, Boston, MA) or with increasing free concentrations of
the D3R antagonist [3H]raclopride (81.9 Ci/mmol; PerkinElmer).
Membranes were incubated with ligands providing enough time to
achieve stable equilibrium for the lower ligand concentrations.
Nonspecific binding was determined in the presence of 30 mM
nonlabeled ligand. Free and membrane-bound ligand were separated
by rapid filtration of 500-ml aliquots in a cell harvester (Brandel,
Gaithersburg, MD) through Whatman GF/C filters embedded in 0.3%
PEI that were subsequently washed for 5 seconds with 5 ml ice-cold
Tris-HCl buffer. The filters were incubated with 10 ml Ultima Gold
MV scintillation cocktail (PerkinElmer) overnight at room tempera-
ture, and radioactivity counts were determined using a Tri-Carb
2800TR scintillation counter (PerkinElmer) with an efficiency of 62%.
Protein was quantified by the bicinchoninic acid method (Pierce
Chemical, Rockford, IL) using bovine serum albumin dilutions as
standard. Saturation curves were analyzed by nonlinear regression,
using the commercial Grafit software (Erithacus Software Q:8). Binding
data were fitted to the two-state dimer receptor model using the
equations previously described for noncooperative ligands in satura-
tion curves (Casadó et al., 2007; Ferré et al., 2014).
Adenylyl Cyclase Assay. A whole cell-cyclic AMP accumulation
assay was used with stably transfected HEK-293 cells expressing D3R
or both D1R and D3R. In some experiments, cells were transiently
transfected with AC5 (2 mg cDNA). Cells were grown, as described
above, and, the day of the assay, medium was removed and
substituted by a Hank’s balanced salt solution buffer. Then cells
were incubated simultaneously with the indicated D1R and D3R
agonists and antagonists 17 minutes at room temperature. To stop
the reaction, incubation buffer was aspirated and 0.1 M HCl was
added. Determination of cAMP levels was performed using an
enzyme-linked immunosorbent assay kit (Enzo Life Sciences, Farm-
ingdale, NY) following the protocol suggested by the provider. The
adenylyl cyclase assay was also used in experiments with Chinese
hamster ovary cell lines stably transfected with adenosine A1
receptors (A1R) or A2A receptors (A2AR) (Orru et al., 2011) to provide
positive controls of the effect of CTX and PTX in experiments of MAPK
signaling.
Results
Ligand-Induced Changes in Gs and Gi Protein
Coupling to the D1R-D3R Heteromer. HEK-293 cells
were transiently transfected with D3R and D1R or with D3R
fused to complementary Rluc hemitruncated proteins and
Gai1 fused to YFP (Fig. 1A). An increase in BRET signal was
observed as a function of the D3R agonist quinpirole
concentration. The results showed that quinpirole induces
Gai1 coupling to D3R in the D3R-D3R homomer (Fig. 1A, black
squares) and the D1R-D3R heteromer (Fig. 1A, filled orange
squares) with close potencies (log EC50, M 5 27.5 6 0.3 and
28.0 6 0.3, respectively). The agonist-induced response was
inhibited by the D3R antagonist raclopride (1 mM) (Fig. 1A,
open orange squares). In HEK-293 cells transiently trans-
fected with D3R and D1R or D1R fused to complementary
Rluc hemitruncated proteins and Gas short fused to YFP (Fig.
1B), the D1R agonist (6)-1-phenyl-2,3,4,5-tetrahydro-(1H)-3-
benzazepine-7,8-diol hydrobromide (SKF 38393) induced
a dose-dependent increase in BRET values. SKF 38393
promoted Gss coupling to D1R in the D1R-D1R homomer
(Fig. 1B, black squares) and the D1R-D3R heteromer (Fig. 1B,
filled orange squares) with close potencies (log EC50, M 5
27.5 6 0.3 and 27.6 6 0.4, respectively). The effect of SKF
38393 was counteracted by the D1R antagonist SCH 23390
(1 mM) (Fig. 1B, open orange squares). Control experiments
also showed that D1R-D1R and D3R-D3R homomers do not
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couple to Gi1 and Gss, respectively (data not shown). These
results indicate that both Gi and Gs are coupled to D1R-D3R
heteromers.
We then evaluated the possible effects of agonists or
antagonists binding to one of the receptors in the heteromer
on agonist-induced G protein coupling in the partner receptor
(cross talk or cross-antagonism). In HEK-293 cells transiently
transfected with D3R and D1R fused to the complementary
Rluc hemitruncated proteins and Gi1 or Gss coupled to
mVenus, SKF 38393- or quinpirole-induced increases in
BRET were determined after the addition of agonists or
antagonists of the other receptor unit in the heteromer. For
quinpirole-induced Gi1 coupling to D1R-D3R heteromers, the
addition of 1 mMSKF 38393 or 1 mMSCH 23390 did not cause
any significant change in EC50 values deduced from
concentration-response BRET curves (Table 1). Similarly,
EC50 values for SKF 38393-induced Gss coupling were not
changed significantly after addition of 1 mM quinpirole or 1
mM raclopride (Table 1). These results indicate that D1R and
D3R in the D1R-D3R heteromer couple to their preferred G
protein subtype irrespective of simultaneous binding of
ligands to the other receptor unit in the heteromer. They also
support that a simultaneous coupling to Gs and Gi proteins in
the D1R-D3R heteromer can take place upon simultaneous
binding of D1R and D3R ligands.
D1R and D3R Oligomerize as Heteromers of Homo-
dimers. Because it would be difficult for two GPCR proto-
mers to simultaneously accommodate two trimeric G protein
molecules due to steric hindrance (Maurice et al., 2011), the
results of CODA-RET experiments fit with the proposed
model of receptor heteromers comprised of two different
homodimers (Ferré et al., 2014). To test this hypothesis, we
combined bimolecular fluorescence complementation with
BRET (Kerppola, 2006; Robitaille et al., 2009). For this
purpose, D1R was fused to the N-terminal or to the C-
terminal hemitruncated protein of Rluc (D1R-nRluc and D1R-
cRluc) that only upon coexpression and complementation can
act as a BRET donor (Fig. 2A). The BRET acceptor protein
was obtained upon complementation of the D3R fused to the
N-terminal portion of the YFP Venus protein (D3R-nYFP) and
the D3R fused to the C-terminal hemitruncated YFP (D3R-
cYFP) (Fig. 2A). When all four receptor constructs were
transfected in the cell, we obtained a positive and saturable
BRET signal (Fig. 2B). As a negative control, only low and
linear BRET was obtained in cells expressing D1R-nRluc,
D1R-cRluc, and the cannabinoid CB1 receptor (CB1R) fused to
the two YFP hemitruncated proteins (CB1R-nYFP and CB1R-
cYFP) (Fig. 2B). Further negative controls included indepen-
dent experiments replacing each receptor fused to its hemi-
truncated protein with the same nonfused (soluble)
hemitruncated protein (Fig. 2C). These results demonstrate
that D1R-D3R heteromers arrange as heterotetramers con-
stituted by D1R and D3R homodimers.
Adenylyl Cyclase Signaling in the D1R-D3R Hetero-
mer. A cell line with stable expression of D1R fused to Rluc
and D3R fused to YFP (D1R-D3R cells) was developed.
Control cell lines with D1R fused to Rluc (D1R cells) and
D3R fused to YFP (D3R cells) were also obtained. Saturation
experiments with [3H]raclopride showed similar Bmax values
in both D3R and D1R-D3R cells (in means6 S.E.M.: 1.16 0.1
and 0.80 6 0.04 pmol/mg protein, respectively). Saturation
experiments with [3H]SCH 23390 also showed similar Bmax
values in both D1R and D1R-D3R cells (0.9 6 0.02 and 0.806
0.01 pmol/mg protein, respectively). D1R-D3R cells had
therefore very similar expression of D1R and D3R, as
expected from an internal ribosomal entry site construction.
D1R-D3R cells showed stable and measurable BRET values
(BRET ratios) due to heteromerization because emission at
510–540 nm after the addition of coelenterazine H was
significantly greater in D1R-D3R cells than in D1R cells
(BRET ratio in means 6 S.E.M.: 0.714 6 0.005 and 0.687 6
0.007 milli-BRET units, respectively; Student’s t test: P 5
0.002; n 5 30).
SKF 38393 promoted a concentration-dependent cAMP
accumulation in D1R-D3R cells (Fig. 3A). However, quinpirole
did not produce any significant effect on forskolin-induced
cAMP accumulation (data not shown). Furthermore, quinpir-
ole (1 mM) did not modify the increase in cAMP levels
produced by SKF 38393 (Fig. 3A; EC50 of 340 and 290 nMwith
and without quinpirole, respectively). Previous studies have
shown that D3R can only inhibit the activity of AC5, which
has been reported not being expressed in HEK-293 cells
(Robinson and Caron, 1997). In agreement, upon transient
transfection of AC5 in D1R-D3R cells, a significant decrease of
forskolin-induced cAMP accumulation by quinpirole (1 mM)
could be demonstrated (Fig. 3B, gray bars). The cAMP
accumulation promoted by SKF 38393 (1 mM) and the
inhibition of forskolin-induced cAMP accumulation promoted
by quinpirole (1 mM) were counteracted by SCH 23390 (10
mM) and raclopride (10 mM), respectively (Fig. 3B). No cross-
TABLE 1
Effect of partner receptor ligands on agonist-induced G protein interaction to D1R-D3R heteromers
CODA-RETQ:13 experiments were performed in human embryonic kidney-293 cells expressing dopamine receptor type 3
(D3R)-L1 and dopamine receptor type 1 (D1R)-L2 (D3R and D1R fused to the N-terminal and C-terminal hemitruncated
Renilla luciferase 8 proteins, respectively) and Gai1-yellow fluorescence protein (YFP) or Gass-YFP. Bioluminescence
resonance energy transfer between complemented hemitruncated Renilla luciferase 8 and G protein-mVenus was
determined as a function of increasing concentrations of quinpirole or (6)-1-phenyl-2,3,4,5-tetrahydro-(1H)-3-
benzazepine-7,8-diol hydrobromide (SKF 38393) in the absence or in the presence of 1 mM SKF 38393, (R)-(+)-7-chloro-
8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride (SCH 23390), quinpirole, or raclopride,
as indicated in Table 1. From the dose-response curves, EC50 values were calculated, and one-way analysis of variance,
followed by post hoc Newman-Keuls test, did not show significant differences between EC50 values.
Receptor G Protein Treatment Log EC50 (M) (mean 6 S.E.M.) n
D3R-L1 + D1R-L2 Gai1-YFP Quinpirole 28.0 6 0.3 3
Quinpirole + SKF 38393 28.3 6 0.2 3
Quinpirole + SCH 23390 27.9 6 0.3 3
Gass-YFP SKF 38393 27.6 6 0.3 8
SKF 38393 + quinpirole 28.0 6 0.2 3
SKF 38393 + raclopride 27.2 6 0.4 8
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antagonism was observed, because raclopride did not revert
the effect of SKF 38393, nor did SCH 23390 revert the effect of
quinpirole (Fig. 3B). These results mirrored those obtained
with CODA-RET experiments, indicating that agonist-
induced G protein–mediated signaling by one of the receptor
units in the heteromer was not counteracted by antagonist
binding to the other receptor unit. The lack of influence of
allosteric interactions in the heteromer on adenylyl cyclase
signaling was also seen upon coactivation of both receptors.
Upon transfection with AC5, a canonical Gi-Gs–mediated
negative interaction at the level of adenylyl cyclase signaling
was observed in D1R-D3R cells, by which 1 mM quinpirole
significantly decreased cAMP accumulation induced by 1 mM
SKF 38393 (Fig. 3C). These results indicate that both Gi and
Gs proteins can simultaneously signal upon coactivation of
both receptors in the D1R-D3R heteromers. Moreover, the
results do not support positive cross talk at the level of
adenylyl cyclase signaling as a biochemical property of D1R-
D3R heteromerization (Fiorentini et al., 2008).
Allosteric Interactions in the D1R-D3R Heteromer
Modulate MAPK Signaling. In D1R-D3R cells, the D1R
agonist SKF 38393, or the D3R agonists quinpirole (data not
shown) and (RS)-trans-7-hydroxy-2-[N-propyl-N-(39-iodo-29-
propenyl)amino]tetralin maleate (7-OH-PIPAT), produced
MAPK activation (increase in ERK1/2 phosphorylation) in
a concentration-dependent manner (Fig. 4, A and B, solid line:
ERK1/2 phosphorylation after subtraction of basal values).
Interestingly, coactivation with 0.1 mM SKF 38393 and 0.1
mM 7-OH-PIPAT produced a strong activating effect (Fig. 4C,
black bars), indicating a synergistic positive cross talk. In fact,
a significant shift to the left in the SKF 38393 concentration-
response curve was obtained with the addition of 0.1 mM 7-
OH-PIPAT (more than twofold increase in potency; see legend
to Fig. 1A for EC50 values and statistical analysis). Further-
more, a significant shift to the left in the 7-OH-PIPAT
concentration-response curve was also observed with the
addition of 0.1 mM SKF 38393 (more than twofold increase in
potency; see legend to Fig. 1B for EC50 values and statistical
analysis). This demonstrates that the potency of an agonist for
either D1R or D3R increases by agonist binding to the partner
receptor. The positive cross talk was not due to nonspecific
effects of the ligands because, in cells only expressing D1R,
the effect of SKF 38393 was not modified by 7-OH-PIPAT (Fig.
4C, white bars), and in cells only expressing D3R the effect of
7-OH-PIPAT was not changed in the presence of SKF 38393
(Fig. 4C, hatched bars).
HIV TAT peptides fused to D1R TM 5, 6, and 7 peptides
(TM5, TM6, and TM7) were tested for their ability to
destabilize the D1R-D3R heteromer and, consequently, the
energy transfer in BRET experiments in D1R-D3R cells
(which express D1R-Rluc and D3R-YFP). Surprisingly, and at
odds with previously published studies (Borroto-Escuela
et al., 2010), the application of peptides (4–40 mM for 60
minutes) significantly inhibited the enzymatic activity of
Rluc, with strong reduction of bioluminescence values.
Reductions about 50% were obtained at peptide concentra-
tions of 40 mM, which, in our hands, invalidates BRET as
a method to evaluate modifications of receptor heteromer
structure induced by synthetic hydrophobic TM-like peptides.
As an alternative method to BRET, we studied the ability of
the TM-like peptides to destabilize D1R-D3R heteromers by
fluorescence complementation experiments. HEK-293 cells
were transfected with D3R fused to the YFP N-terminal
fragment (nYFP) and D1R fused to the YFP C-terminal
fragment (cYFP). Fluorescence could be detected after YFP
Fig. 2. Tetrameric structure of D1R-D3R heteromers. (A) Schematic
representation of BRET and bimolecular fluorescence complementation of
D1R-nRluc with D1R-cRluc and D3R-nYFP with D3R-cYFP. (B) BRET
saturation curve was obtained in HEK-293 cells transfected with 0.75 mg
cDNA corresponding to D1R-cRluc and D1R-nRluc and increasing
amounts of cDNA corresponding to D3R-nYFP and D3R-cYFP (equal
amounts for each construct). As a negative control, low and linear BRET
was obtained in HEK-293 cells transfected with 0.75 mg cDNA
corresponding to D1R-cRluc and D1R-nRluc and increasing amounts of
cDNA corresponding to CB1R-nYFP and CB1R-cYFP (equal amounts for
each construct). Milli-BRET units (mBU) are represented versus the ratio
between the fluorescence of the acceptor and the luciferase activity of the
donor (YFP/Rluc). Data are mean 6 S.D. of three different experiments
grouped as a function of the amount of BRET acceptor. (C) Positive BRET
obtained in HEK-293 cells transfected with the cDNA corresponding to
D1R-cRluc (0.75 mg), D1R-nRluc (0.75 mg), D3R-nYFP (1 mg), and D3R-
cYFP (1 mg) was compared with that obtained in cells in which the cDNA
corresponding to each one of the receptors fused to its hemitruncated
protein was replaced by the same amount of cDNA corresponding to the
nonfused hemitruncated protein. Values are means 6 S.E.M. of three
different experiments.
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reconstitution, due to a close receptor-receptor interaction
(25,000 6 5000 fluorescence units/20 mg protein). When cells
were treated for 1 hour with 4 mMD1R TM peptides, TM5 and
TM6 alone or in combination, but not TM7, a significant
decrease of YFP fluorescence was found (Fig. 5A). Comple-
mentation was also achieved, albeit with less efficiency, with
cells expressing D1R fused to nYFP and D3R fused to cYFP
(Fig. 5B). Again, fluorescence was significantly decreased
with D1R TM5 and TM6, but not with TM7 (Fig. 5B). As
controls for peptide selectivity, complementation experiments
were performed in cells expressing D3R fused to cYFP and
nYFP. None of the peptides modified D3R-cYFP/D3R-nYFP
complementation (Fig. 5C). Moreover, complementation
experiments were performed in cells expressing D1R fused
to cYFP and nYFP. In these cells, D1R TM5, but not TM6, also
decreased D1R-cYFP/D1R-nYFP complementation (Fig. 5D),
although the effect was less pronounced than for D1R-cYFP/
D3R-nYFP and D3R-cYFP/D1R-nYFP complementation. Of
note, in preliminary experiments to develop the assay, it was
observed that TM peptides (4–40 mM) did not produce
a significant change of fluorescence in cells expressing YFP
Venus alone or cells expressing D3R or D1R fused to the
entire YFP Venus.
Together, these results indicate that selective peptides can
disrupt the quaternary structure of the D1R-D3R heteromer,
and could potentially be used as tools to explore its bio-
chemical properties. Thus, D1R-D3R cells were treated for 1
hour with 4 mM D1R TM5, TM6, or TM7 prior to stimulation
with 0.1 mM 7-OH-PIPAT or SKF 38393 alone or in
combination, and ERK1/2 phosphorylation was determined.
Significantly, in D1R-D3R cells, incubation with D1R TM5
and TM6, but not TM7, disrupted the positive cross talk of
SKF 38393 plus 7-OH-PIPAT (Fig. 6). These results indicate
that the positive cross talk between D1R and D3R agonist at
the level of MAPK signaling is a specific biochemical property
of the D1R-D3R heteromer, because it can only be observed
upon the appropriate quaternary structure of the heteromer.
Cross-antagonism at the MAPK level was also found to be
a biochemical property of the D1R-D3R heteromer. In D1R-
D3R cells, the D1R antagonist SCH 23390 (1 mM) not only
antagonized ERK1/2 phosphorylation induced by 0.1 mMSKF
38393, but also by 0.1 mM 7-OH-PIPAT (Fig. 7, black bars).
Similarly, the D3R antagonist raclopride (1 mM) antagonized
the effect of both SKF 38393 and 7-OH-PIPAT (Fig. 7, black
bars). Cross-antagonism could not be explained by a lack of
ligand specificity, because raclopride (1 mM) did not counter-
act ERK1/2 phosphorylation induced by 0.1 mM SKF 38393 in
D1R cells (Fig. 7, white bars), and SCH 23390 (1 mM) did not
modify ERK1/2 phosphorylation induced by 0.1 mM 7-OH-
PIPAT in D3R cells (Fig. 7, hatched bars). Again, incubation
for 1 hour with 4 mM D1R TM5 and TM6, but not TM7,
disrupted the cross-antagonism of SCH 23390 on 7-OH-
PIPAT–induced ERK1/2 phosphorylation in D1R-D3R cells
(Fig. 8A) and of raclopride on SKF 38393-induced ERK1/2
phosphorylation (Fig. 8B). These results demonstrate that
allosteric interactions between ligands (positive cross talk and
Fig. 3. Adenylyl cyclase signaling in D1R-D3R cells. cAMP accumulation
was determined in D1R-D3R cells. (A) Cells were stimulated with
increasing concentrations of the D1R agonist SKF 38393 in the absence
(white symbols) or the presence (black symbols) of 1 mM quinpirole. (B)
Cells were not transfected (black columns) or transfected (gray columns)
with AC5. Cells were pretreated or not for 15 minutes with 10 mM D3R
antagonist raclopride or D1R antagonist SCH 23390 prior to stimulation
with SKF 38393 (1 mM) or quinpirole (1 mM) plus forskolin (1 mM). Values
represent means 6 S.E.M. (n = 4–11) of the percentage of cAMP
accumulation relative to basal levels found in transfected or non-
transfected cells. (C) Cells transfected with AC5 were stimulated with
SKF 38393 (1 mM), quinpirole (1 mM), or both. Values are expressed as
percentage over basal and are means 6 S.E.M. (n = 7–10). Significant
differences were calculated by one-way analysis of variance with post hoc
Newman-Keuls test: ***P , 0.001 versus basal values; ###P , 0.001 versus
SKF 38393; ##P , 0.01 versus forskolin.
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cross-antagonism) in the D1R-D3R heteromer modulate
MAPK signaling.
The results described above indicate the existence of
a functional selectivity of allosteric interactions in the D1R-
D3R heteromer, because they are not involved in ligand-
induced G protein coupling or G protein–mediated signaling
(adenylyl cyclase), but are involved in MAPK activation. To
demonstrate that agonist-induced ERK1/2 phosphorylation is
G protein–independent, we performed experiments in the
presence of PTX and CTX. In D1R-D3R cells, ERK1/2
phosphorylation induced by SKF 38393 or 7-OH-PIPAT was
unchanged after treatment with CTX or PTX, and neither
toxin modified the positive cross talk between D1R and D3R
agonists (Fig. 9A). Parallel control experiments using the
same conditions were performed in Chinese hamster ovary
cell lines expressing A1R or A2AR (Orru et al., 2011) to
provide positive controls of the effect of CTX and PTX. In A1R-
expressing cells, PTX, but not CTX, counteracted the ability of
an A1R agonist (N-cyclopentyladenosine) to inhibit forskolin-
induced cAMP accumulation. In A2AR-expressing cells, CTX,
but not PTX, counteracted the ability of an A2AR agonist
(4-[2-[[6-amino-9-(N-ethyl-b-D-ribofuranuronamidosyl)-9H-
purin-2-yl]amino]ethyl]benzenepropanoicacid hydrochloride;
CGS 21680) (data not shown). We then explored whether the
allosteric changes observed at the level of MAPK signaling
could also be observed at the level of b-arrestin-1 recruitment,
because b-arrestin recruitment-dependent MAPK signaling
has been well established for several GPCRs (Kovacs et al.,
2009). In cells expressing D3R fused to YFP, b-arrestin-1-
Rluc, and D1R, a strong recruitment of b-arrestin-1 was
observed in BRET experiments upon coadministration of SKF
38393 and 7-OH-PIPAT. Furthermore, cross-antagonism of
SKF 38393-induced b-arrestin-1 recruitment with raclopride
and 7-OH-PIPAT–induced b-arrestin-1 recruitment with
SCH 23390 was also demonstrated (Fig. 9B, black bars).
Importantly, b-arrestin-1 recruitment was induced not only
with the D3R agonist, 7-OH-PIPAT, but also with the D1R
agonist SKF 38393, indicating recruitment of b-arrestin by
the D1R-D3R heteromer unit (Fig. 9B, black bars). As
a negative control, in cells expressing D3R fused to YFP and
b-arrestin-1-Rluc, but not D1R, SKF 38393 was not able to
induce b-arrestin-1 recruitment. Finally, either D1R agonists
or antagonists did not significantly modify 7-OH-PIPAT–
induced recruitment of b-arrestin-1 (Fig. 9B, gray bars).
These results indicate that allosteric interactions in the D1R-
D3R heteromer selectively modulate G protein–independent
MAPK signaling and b-arrestin-1 recruitment.
Fig. 4. Agonist-induced ERK1/2 phosphorylation in D1R, D3R, or D1R-
D3R cells. (A) ERK1/2 phosphorylation was determined in D1R-D3R cells
stimulated with increasing concentrations of the D1R agonist SKF 38393
in the absence (solid line; EC50 = 15 6 3 nM; n = 3) or in the presence
(broken line; EC50 = 6 6 1 nM; n = 3) of the D3R agonist 0.1 mM 7-OH-
PIPAT. (B) ERK1/2 phosphorylation was determined in D1R-D3R cells
stimulated with increasing concentrations of 7-OH-PIPAT in absence
(solid line; EC50 = 246 4 nM; n = 3) or presence (broken line; EC50 = 96 2
nM; n = 3) of 0.1 mM SKF 38393. (A) and (B) Values are expressed as the
means 6 S.E.M., subtracting basal values from control untreated cells (A
and B, solid lines) and subtracting the values obtained with 7-OH-PIPAT
alone (A, broken line) or SKF 38393 alone (B, broken line). Significant
differences were obtained between EC50 values of SKF 38393 and SKF
38393 plus 7-OH-PIPAT (A) and between EC50 values of 7-OH-PIPAT and
7-OH-PIPAT plus SKF 38393. Student’s t test: P , 0.05 in both cases. (C)
ERK1/2 phosphorylation was determined in D1R-D3R cells (black
columns), D1R cells (white columns), or D3R cells (hatched columns).
Cells were not treated (basal) or treated with SKF 38393 (0.1 mM) and 7-
OH-PIPAT (0.1 mM) alone or in combination. Values are expressed as
percentage over basal and are means 6 S.E.M. (n = 6). Significant
differences were calculated by one-way analysis of variance with post hoc
Newman-Keuls test: *P, 0.05, **P, 0.01, and ***P, 0.001 versus basal
values.
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Discussion
Increasing attention is being given to the D1R-D3R
heteromer as a potential therapeutic target for a variety of
neuropsychiatric disorders, including Parkinson’s disease and
drug addiction (Fiorentini et al., 2010; Ferré et al., 2010,
2014). From our study, three major conclusions can be made.
First, D1R-D3R heteromers arrange as heterotetramers
consisting of D1R and D3R homodimers able to couple to Gs
and Gi proteins, respectively. This arrangement promotes the
canonical negative interaction at the level of adenylyl cyclase
signaling. Second, allosteric interactions between ligands
take place within the D1R-D3R heteromer that allows
Fig. 5. Effect of D1R TAT-TM-like peptides on D1R-D3R heteromerization detected by fluorescence complementation experiments. HEK-293 cells
expressing (A) D3R fused to the YFP N-terminal fragment (nYFP) and D1R fused to the YFP C-terminal fragment (cYFP); (B) D1R fused to nYFP and
D3R fused to cYFP; (C) D3R fused to cYFP and D3R fused to nYFP; and (D) D1R fused to cYFP and D1R fused to nYFP. Fluorescence at 530 nm was
determined in cells treated or not treated (control or Ctr) for 1 hour with 4 mMD1R TM peptide TM5, TM6, or TM7 alone or a combination of TM5 plus
TM6. Values are expressed as percentage over the fluorescence detected in the absence of peptides and are means 6 S.E.M. (n = 4). Significant
differences were calculated by one-way analysis of variance with post hoc Newman-Keuls test: **P , 0.01 versus control.
Fig. 6. Effect of D1R TAT-TM-like peptides on agonist-induced ERK1/2
phosphorylation in D1R-D3R cells. Cells were not treated (black columns)
or treated for 1 hour with 4 mMTM5, TM6, or TM7 before stimulation with
the D1R agonist SKF 38393 (0.1 mM), the D3R agonist 7-OH-PIPAT
(0.1 mM), or both. Values are expressed as percentage over basal and are
means6 S.E.M. (n = 6). Significant differences were calculated by one-way
analysis of variance with post hoc Newman-Keuls test. *P , 0.05, **P ,
0.01, and ***P , 0.001 versus basal values; ##P , 0.01 as compared with
SKF 38393 + 7-OH-PIPAT in the control group.
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selective modulation of G protein–independent MAPK sig-
naling and b-arrestin-1 recruitment. Third, peptides compet-
ing for GPCR TM domains provide useful tools to probe GPCR
heteromerization.
A D3R agonist-mediated potentiation of D1R agonist-
mediated signaling through adenylyl cyclase was initially
suggested as a biochemical property of the D1R-D3R hetero-
mer (Fiorentini et al., 2008). It was also suggested that a main
allosteric mechanism responsible for this putative biochem-
ical property is a D3R agonist-mediated increase in the
affinity of D1R agonists (Marcellino et al., 2008). In the
present study, we wanted first to evaluate whether changes in
G protein coupling could also be involved. The recently
introduced CODA-RET assay specifically allows detecting
ligand-induced conformation changes in the receptor–G pro-
tein interface of a defined G protein–coupled receptor
oligomer (Urizar et al., 2011). Using this technique, we could
then demonstrate that, upon agonist binding, D1R interacts
with Gs and D3R interacts with Gi when forming homomers or
heteromers. It has been argued that two protomers in a GPCR
oligomer are insufficient to simultaneously accommodate two
trimeric G protein molecules (Maurice et al., 2011). Our
results using CODA-RET experiments fit with the proposed
model of receptor heteromers comprised of two different
homodimers, each able to signal with their preferred G
protein (Ferré et al., 2014). In fact, in the present study,
a heterotetrameric structure of the D1R-D3R heteromer could
be demonstrated with BRET experiments using double
bimolecular complementation of Rluc and YFP.
We could not confirm the previously reported existence of
a positive cross talk at the level of adenylyl cyclase in HEK-
293 cells expressing D1R and D3R, by which a D3R agonist
potentiates D1R agonist-induced adenylyl cyclase activation
(Fiorentini et al., 2008). In fact, CODA-RET experiments in
transiently transfected cells showed that, in the D1R-D3R
receptor heteromer, a D3R agonist does not modify the
potency of a D1R agonist to induce a Gs conformational
change. Furthermore, in agreement with previous studies,
D3R activation did not inhibit forskolin-induced cAMP
accumulation in HEK-293 cells (Robinson and Caron, 1997).
This is related to the fact that D3R can only inhibit the
activity of AC5, which is not expressed in HEK-293 cells
(Robinson and Caron, 1997). When AC5 was cotransfected to
D1R-D3R cells, D3R activation was not only able to inhibit
forskolin- but also D1R agonist-induced cAMP accumulation.
Therefore, differences in AC5 expression could explain at
least part of the discrepancies between the previously
reported study (Fiorentini et al., 2008) and the present
results. In the brain, D1R and D3R are mostly colocalized in
the striatum, in GABAergic efferent neurons that express
AC5 as the predominant type of adenylyl cyclase (Lee et al.,
2002). Our results therefore suggest that in the brain, if D1R-
D3R heteromers are significantly represented, the Gi-de-
pendent D3R-mediated activation should lead to a reduced
Gs-dependent D1R-mediated activation of adenylyl cyclase
signaling.
One important question is, therefore, what is the mecha-
nism involved in the synergistic effects of D1R and D3R
agonists observed at the behavioral level (Marcellino et al.,
2008). Either D1R-D3R heteromers are not involved or the
behavioral results depend on signaling pathways other than
adenylyl cyclase activation. We did find a positive cross talk of
D1R and D3R agonists, but at the level of MAPK signaling.
Furthermore, a strong recruitment of b-arrestin-1 was
observed in BRET experiments upon coadministration of
SKF 38393 and 7-OH-PIPAT. The positive cross talk at the
MAPK level was counteracted by the same peptides that
modified the quaternary structure of the heteromer (D1R
TM5 and TM6, but not TM7), as demonstrated in YFP-
complementation experiments. This indicates that a selective
positive cross talk of D1R and D3R receptor agonists at the
MAPK level represents a biochemical property of the D1R-
D3R receptor heteromer. The synthetic peptide strategy could
not be used in b-arrestin-1 recruitment BRET-based experi-
ments because of their direct inhibitory effects on Rluc
activity (see Results). Nevertheless, the ability of the D1R
agonist to promote b-arrestin-1-Rluc recruitment to D3R-YFP
in the heteromer indicates its dependence on D1R-D3R
receptor heteromerization. D1R-D3R heteromer-mediated
MAPK signaling and b-arrestin-1 recruitment could therefore
be major players involved in the synergistic motor-activating
effects of D1R and D3R agonists (Marcellino et al., 2008).
Cross-antagonism has been previously suggested to be
a biochemical property of several receptor heteromers, such as
for D1R-histamine H3 receptor and a a1B and b1 adrenergic
receptor–dopamine D4 receptor heteromers (Gonzalez et al.,
2012; Moreno et al., 2014). Cross-antagonism would imply an
allosteric interaction between ligands by which an antagonist
of one receptor in the heteromer blocks the agonist-induced
activation of the partner receptor in the heteromer. Although
Fig. 7. Effect of D1R and D3R antagonists on agonist-
induced ERK1/2 phosphorylation in D1R-D3R cells. ERK1/2
phosphorylation was determined in D1R-D3R cells (black
columns), D1R cells (white columns), or D3R cells (hatched
columns). Cells were pretreated for 15 minutes with 1 mM
D3R antagonist raclopride or D1R antagonist SCH 23390
prior to stimulation with 0.1 mMD1R agonist SKF 38393 or
D3R agonist 7-OH-PIPAT. Values are expressed as percent-
age over basal and are means6 S.E.M. (n = 5–6). Significant
differences were calculated by one-way analysis of variance
with post hoc Newman-Keuls test. *P , 0.05, **P , 0.01,
***P , 0.001 versus basal values; ##P , 0.01 and ###P ,
0.001, as compared with SKF 38393 or 7-OH-PIPAT.
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it is difficult to envision a mechanism for cross-antagonism
that does not depend on the existence of direct intermolecular
receptor interactions, dependence on the right quaternary
structure should be established to unequivocally demonstrate
that cross-antagonism is a biochemical property of a receptor
heteromer. In the present study, with the use of selective
disrupting peptides, we provide direct evidence for cross-
antagonism as a biochemical property of the D1R-D3R
heteromer. Again, this biochemical property was only selec-
tive for MAPK signaling, and it was not observed in cAMP
experiments in D1R-D3R cells or CODA-RET experiments in
transiently transfected cells. Cross-antagonism at the MAPK
level could be secondary to an allosteric modulation at the
level of b-arrestin-1 recruitment, in which cross-antagonism
was also observed. Thus, G protein–independent and
b-arrestin–dependent MAPK signaling has been well estab-
lished for several GPCRs (Kovacs et al., 2009). In fact, CTX
and PTX treatments could not counteract ERK1/2 activation
induced by D1R and D3R agonists, respectively. Altogether,
Fig. 8. Effect of D1R TM peptides on cross-antagonism of agonist-induced
ERK1/2 phosphorylation in D1R, D3R, or D1R-D3R cells. ERK1/2
phosphorylation was determined in cells not treated (control) or treated
for 1 hour with 4 mM TM5, TM6, or TM7. Cells were incubated for 15
minutes with 1 mM D1R antagonist SCH23390 (A) or D3R antagonist
raclopride (B) before stimulation with 0.1 mM D3R agonist 7-OH-PIPAT
(A) or the D1R agonist SKF 38393 (B). Values are expressed as percentage
of agonist-induced phosphorylation in control conditions and are means 6
S.E.M. (n = 4–5). Significant differences were calculated by Student’s
t test: *P , 0.05, **P , 0.01 versus 7-OH-PIPAT or SKF 38393-treated
control cells in each condition (A or B).
Fig. 9. G protein–independent mechanisms of the allosteric modulations
in the D1R-D3R heteromer. (A) D1R-D3R cells were treated overnight
with vehicle (black columns), with 10 ng/ml pertussis toxin (PTX, white
columns), or with 100 ng/ml cholera toxin (CTX, gray columns). Cells were
not stimulated (basal) or stimulated with 0.1 mM D1R agonist SKF 38393
or the D3R agonist 7-OH-PIPAT alone or in combination. Values are
expressed as percentage over basal and are means 6 S.E.M. (n = 5). (B)
HEK-293T cells were transfected with the cDNA corresponding to D3R-
YFP (1 mg cDNA) and b-arrestin-1-Rluc (0.5 mg cDNA) in the absence (gray
columns) or presence of D1R (1.5 mg cDNA) (black columns). Forty-eight
hours post-transfection, cells were treated with vehicle or 1 mM D3R
antagonist raclopride or the D1R antagonist SCH23390 before stimulation
with 0.1 mM7-OH-PIPAT or SKF 38393, and b-arrestin-1 recruitment was
measured by BRET experiments. Values are means 6 S.E.M. (n = 7–8).
Significant differences were calculated by one-way analysis of variance
with post hoc Newman-Keuls test: *P , 0.05, ***P , 0.001 versus basal
values; (B) ###P , 0.001 as compared with agonist alone.
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the present study indicates the existence of a functional
selectivity of the allosteric interactions in the D1R-D3R
heteromer, which modulate G protein–independent and
b-arrestin–dependent signaling, but not G protein activation.
The differential modulation of G protein–dependent and
independent signaling in D1R-D3R heteromers observed in
the present study is difficult to reconcile with the idea that
a main biochemical property of the D1R-D3R receptor
heteromer is the ability of D3R activation to increase the
affinity of D1R agonists (Fiorentini et al., 2008; Marcellino
et al., 2008). In that case, D3R agonists should have also
potentiated D1R-mediated Gs protein activation and adenylyl
cyclase signaling (which we did not observe either in the
presence or the absence of AC5). Instead, we observed
identical concentration-response curves of D1R agonist-
induced Gs conformational changes in transiently transfected
cells and cAMP accumulation in D1R-D3R cells with or
without concomitant exposure to the D3R agonist. Our results
therefore indicate that the previously reported changes in
affinity of D1R agonists upon D3R activation are not observ-
able in all experimental conditions and might not only be
dependent on D1R-D3R heteromerization.
The present study confirms the validity of the synthetic-
peptide approach. It is at least safe to say that it can be
successfully used to demonstrate that a biochemical finding
corresponds to a biochemical property of a GPCR oligomer.
The ability of selective peptides to simultaneously induce
a modification of the quaternary structure of the D1R-D3R
heteromer (alteration of YFP complementation) and to
disrupt specific allosteric interactions of D1R andD3R ligands
allowed establishing these as biochemical properties of the
heteromer. Furthermore, comparing the effects of the same
D1R TM peptides on the quaternary structure of D1R-D3R,
D1R-D1R, and D3R-D3R oligomers allowed making some
inferences about the oligomeric interfaces. The D1R TM5 and
TM6 peptides significantly modified the quaternary structure
of D1R-D3R. Interestingly, D1R TM5 peptide was also able to
reduce D1R-D1R complementation, whereas TM6 and TM7
had no effect. This would suggest that D1R TM5 forms part of
the D1R-D3R heteromer and D1R-D1R homomer interfaces.
Importantly, D1R TM5- and TM6-mediated functional dis-
ruption was specific for the allosteric interactions between
D1R and D3R ligands modulating MAPK signaling, without
affecting the direct signaling mediated by D1R or D3R
agonists, suggesting that D1 TM5 and TM6 are part of the
conduit of those allosteric interactions.
Functional selectivity has gained more attention in GPCR
research, because it can provide the means to obtained drugs
with less secondary effects, avoiding nonwanted side effects
associated with one of the signaling pathways (Reiter et al.,
2012; Shonberg et al., 2014Q:9 ). Disentangling the intimate
molecular mechanisms and conformational changes involved
in the allosteric interactions in the D1R-D3R heteromermight
therefore bring new aspects in the field. It has been postulated
that the D1R-D3R heteromer constitutes an important
functional unit in the brain and that it plays a role in several
neuropsychiatric disorders, such as L-dopa–induced dyskine-
sia and drug addiction (Ferré et al., 2010, 2014), conditions in
which there is upregulation of D3R (Staley and Mash, 1996;
Ferré et al., 2010). As already shown in preclinical models of
both conditions, dopamine D3R antagonists should be
particularly useful, according to our study, by blocking both
D3R- and D1R-mediated b-arrestin-1–dependent MAPK
signaling in the striatal D1R-D3R heteromer. Our study
suggests that evaluation of the effects of different ligands in
D1R-D3R heteromer-expressing cell lines may provide new
tools for the understanding of the pathophysiology and
treatment of these disorders.
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